Kidney and Thyroid Cancer-Specific Treatment Algorithm for Spinal Metastases: A Validation Study

• Published in: World neurosurgery Vol. 122; pp. e1305 - e1311
• Main Authors: Kato, Satoshi, Murakami, Hideki, Demura, Satoru, Yoshioka, Katsuhito, Yokogawa, Noriaki, Yonezawa, Noritaka, Shimizu, Takaki, Oku, Norihiro, Kitagawa, Ryo, Tsuchiya, Hiroyuki
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019
• Subjects: Kidney cancer; Spinal metastases; Thyroid cancer; Treatment algorithm; Validation study; Thyroid cancer; NPV; ECOG-PS; Kidney cancer; PPV; Spinal metastases; Treatment algorithm; Validation study
• ISSN: 1878-8750; 1878-8769
• DOI: 10.1016/j.wneu.2018.11.040

Spinal metastases (SMs) from kidney and thyroid cancers have several common features suggesting that excisional surgery for isolated and removable SMs can improve survival. We propose a simple treatment algorithm for SMs from these cancers. Our study aimed to evaluate the efficacy of the algorithm. We performed a retrospective analysis of the data of 69 consecutive patients (48 with kidney and 21 with thyroid cancers) who underwent excisional surgery for SMs between 1995 and 2014. The patients were retrospectively classified into an indicated group for excisional SM surgery and a nonindicated group according to our algorithm, and the Tokuhashi and Tomita scoring systems. Patients in the indicated group were expected to survive ≥2 years postoperatively, whereas those in the nonindicated group were not. The positive predictive value and negative predictive value (NPV) were calculated using the predicted versus actual survival times of the patients. Survival was defined as the time from the first excisional surgery for the spinal lesion to death or the last follow-up of ≥2 years. For patients with kidney cancer, the 2- and 5-year survival rates were 85.4% and 60.4%, respectively. For patients with thyroid cancer, the 2- and 5-year survival rates were 100% and 83.8%, respectively. Our algorithm had a compatible high positive predictive value (95.5%) and NPV (100%), whereas the Tokuhashi and Tomita scoring systems had low NPVs of 15.8% and 13.3%, respectively. Our treatment algorithm of SMs from kidney and thyroid cancers is useful for determining an adequate treatment including excisional surgery.